- Pfizer has purchased an 8.1% stake in Valneva.
- The companies are collaborating on a Lyme disease vaccine.
- PFE stock recently broke through long-term support.
With markets closed for the Juneteenth holiday on Monday, Pfizer (PFE) announced a $95.2 million stake in French vaccine maker Valneva, according to Reuters. The investment gives Pfizer an 8.1% position as an important partner that it has been collaborating with the American pharma major on a Lyme disease vaccine. PFE shares fell 2% to $46.54 on Friday, but Valneva shares (VLA.PA) rocketed 17.9% higher to €9.36 on Monday at the time of writing.
Pfizer Stock News: Stage 3 trials for Lyme disease vaccine await
Pfizer and Valneva have been working in partnership on the Lyme disease vaccine since April of 2020. With Pfizer's added liquidity, Valneva will now shoulder 40% of continued development costs rather than the original 30%. The two companies are planning to launch their state 3 trials for the VLA15 vaccine candidate in the third quarter of 2022.
"Pfizer's investment in Valneva highlights the quality of the work that we’ve done together over the past two years and is a strong recognition of Valneva's vaccine expertise," said Valneva CEO Thomas Lingelbach.
A vaccine for Lyme disease, which is caused by bacteria from ticks, existed in the late 1990s but was abandoned after several years due to low demand. In this present case, Pfizer will pay Valneva various levels of royalties ranging from 14% to 22%. Up to $100 million extra will be paid to Valneva based on cumulative sales and other achievements.
Pfizer Stock Forecast: PFE breaks through long-term support
At first glance, the Pfizer daily stock chart below seems to show a reasonable consolidation structure in the price action. Since January, PFE shares have rotated between $45 and $56, and the chart is not characterized by the never-ending sell-off that has affected so many other mega-cap stocks, especially those in the tech space. At $261 billion, Pfizer is definitely a mega-cap. Bearing a 3.4% dividend, Pfizer is safer than many other stocks in this poor environment for equities as it is quite liquid and dispersed so widely among retail and institutions alike. Additionally, many shareholders use their dividends to reinvest in new shares of the company, which gives it a kind of natural floor.
Below you can see that there is a wide demand zone between $45 and $48 where the market has a tendency to buy the dip. Above here resistance is also represented by a broad supply zone between $54 and $56.
PFE daily chart YTD
Panning out for a longer-term view, however, showcases a worrying sign. The ascending support line that began in March 2021 was broken on June 13. Breaking through 15 months of support is nearly always a bad sign. If PFE stock breaks through support at $45, then support from October of 2021 lingers nearby at $41. This might be good news for long-term investors, who will continue holding it for the steady payouts, but traders will see it as evidence that PFE is not a good bet.
Though the Relative Strength Index (RSI) is oversold, the Moving Average Convergence Divergence (MACD) indicator is crossed over in the wrong direction and moving below the zero threshold. It would seem this is not the time to long Pfizer stock.
PFE daily chart over 2-year period
Like this article? Help us with some feedback by answering this survey:
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.